AVROBIO

55 articles with AVROBIO

• AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sep 04, 2020

  9/4/2020

  AVROBIO, Inc., a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, announced that the company has granted a non-statutory stock option for the purchase of up to 63,000 shares of the company’s common stock to one new employee as an inducement award under the company’s 2019 Inducement Plan, in accordance with Nasdaq Listing Rule 5635.

• AVROBIO to Present at Three Upcoming Investor Conferences - Sep 03, 2020

  9/3/2020

  AVROBIO, Inc., a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, announced that members of its senior management team are scheduled to participate in three upcoming virtual investor conferences.

• AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 07, 2020

  8/7/2020

  AVROBIO, Inc. announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 34,500 shares of the company’s common stock to three new employees as inducement awards under the company’s 2019 Inducement Plan, in accordance with Nasdaq Listing Rule 5635.

• AVROBIO Reports Second Quarter 2020 Financial Results and Provides Business Update

  8/6/2020

  New data indicate stable kidney function across the two Fabry disease clinical studies up to 32 months New six-month Phase 2 FAB-201 data from first patient treated using AVROBIO’s plato ® gene therapy platform show continued reduction in toxic metabolite plasma lyso-Gb3 and increased leukocyte and plasma enzyme activity Sustained clinical data across multiple other measures for Phase 1 and Phase 2 trials for Fabry disease First patient h

• AVROBIO to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

  8/5/2020

  AVROBIO, Inc . (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference at 1:10 p.m. ET on Wednesday, Aug. 12, 2020. A live webcast of the presentation can be accessed under "Events and Presentations" in the Investors

• AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 08, 2020

  7/8/2020

  AVROBIO, Inc. announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 138,200 shares of the company’s common stock to five new employees as inducement awards under the company’s 2019 Inducement Plan, in accordance with Nasdaq Listing Rule 5635.

• AVROBIO Announces New Patients Dosed in Gaucher Disease and Cystinosis Clinical Trials

  7/6/2020

  AVROBIO, Inc., a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, announced that the first patient has been dosed in the company’s GuardOne clinical trial, a Phase 1/2 investigational study evaluating AVR-RD-02 for Gaucher disease type 1.

• AVROBIO Announces the Appointment of Kim Raineri as Chief Manufacturing and Technology Officer

  6/29/2020

  AVROBIO co-founder and veteran gene and cell therapy pioneer Kim Warren to retire July 31, 2020

• AVROBIO Presents New Preclinical Data on Lentiviral Gene Therapy Program for Pompe Disease at ASGCT 2020

  5/14/2020

  AVROBIO’s optimized lentiviral vectors demonstrate significant glycogen reduction in the muscle and central nervous system of Pompe disease mouse model Investigational New Drug (IND)-enabling proof-of-concept study for AVR-RD-03 for Pompe disease currently underway CAMBRIDGE, Mass.--( BUSINESS WIRE )-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease,

• AVROBIO Reports Updated Clinical Data from Investigational Gene Therapy Programs for Fabry Disease and Cystinosis

  5/13/2020

  Sustained enzyme activity up to 22 months and consistent trends demonstrated across multiple other measures in first patient in Fabry disease Phase 2 clinical trial Data from first patient treated using plato TM gene therapy platform in Fabry disease trial show: 43-percent reduction in toxic metabolite plasma lyso-Gb3 one month post-treatment Significantly higher leukocyte and plasma enzyme activity three months post-treatmen

• AVROBIO Reports 1Q 2020 Financial Results and Provides Business Update

  5/7/2020

  Three oral presentations accepted on new clinical and preclinical data at the American Society of Gene and Cell Therapy (ASGCT) 23rd annual meeting Completed two collaboration agreements to reinforce technological leadership in lentiviral gene therapy Raised $100 million in gross proceeds from follow-on stock offering in February 2020, strengthening our balance sheet with more than two years of cash runway

• AVROBIO and Magenta Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies

  5/6/2020

  Collaboration focuses on advancing innovation with antibody-drug conjugate (ADC)-based conditioning for lentiviral gene therapies

• AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 06, 2020

  5/6/2020

  AVROBIO, Inc. announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 117,000 shares of the company’s common stock to four new employees as inducement awards under the company’s 2019 Inducement Plan, in accordance with Nasdaq Listing Rule 5635.

• AVROBIO to Present New Clinical and Preclinical Data at Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 12-15, 2020

  5/5/2020

  Updated data will be presented on first patient dosed in Phase 1/2 clinical trial for cystinosis and first patient treated using plato™ gene therapy platform in Phase 2 Fabry disease clinical trial

• AVROBIO to Collaborate with Saladax Biomedical on New High-Speed Diagnostic Assay Used with Busulfan Conditioning to Enable Widespread Commercialization of AVROBIO’s Proprietary Platform Globally

  5/4/2020

  Fully automated immunoassay kit designed to simplify and streamline busulfan therapeutic drug monitoring (TDM), potentially reducing turnaround time from hours to minutes and greatly expanding hospital, clinic, medical office and laboratory access to TDM

• AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 3, 2020

  4/3/2020

  AVROBIO, Inc. announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 111,750 shares of the company’s common stock to eight new employees as inducement awards under the company’s 2019 Inducement Plan, in accordance with Nasdaq Listing Rule 5635.

• AVROBIO to Participate in Upcoming April Investor Conferences

  3/26/2020

  AVROBIO, Inc . today announced that members of its senior management team will participate at three upcoming virtual investor conferences: Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day Panel Presentation: Viral Vector Manufacturing: Current State of Play in Indu

• AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - March 25, 2020

  3/25/2020

  AVROBIO, Inc. announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 63,000 shares of the company’s common stock to one new employee as an inducement award under the company’s 2019 Inducement Plan, in accordance with Nasdaq Listing Rule 5635.

• AVROBIO Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update

  3/16/2020

  AVROBIO reports fourth quarter and fiscal year 2019 results

• AVROBIO Receives Orphan Drug Designation from U.S. FDA for AVR‑RD‑04 for Cystinosis

  3/9/2020

  AVROBIO, Inc. announced that the U.S. Food and Drug Administration has granted orphan drug designation to the company’s investigational gene therapy, AVR-RD-04, for the treatment of cystinosis.